Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David E Neal

Showing results (1-10 of 302) with videos related to

Pageof 31
Sort By:
The Lancet. Oncology|July 6, 2010
PSA testing for prostate cancer improves survival--but can we do better?David E Neal
Nature Clinical Practice. Urology|February 14, 2006
Molecular medicine and its impact on practiceDavid E Neal
The Journal of Urology|August 19, 2008
Can we accurately identify men with low risk prostate cancer?David E Neal
BJU International|April 5, 2013
Targeting the pro-survival side-effects of androgen-deprivation therapy in prostate cancerVincent Zecchini, David E Neal
The Practitioner|December 3, 2003
Key questions in benign prostatic hyperplasiaDavid E Neal, Paul Hegarty
BMJ (Clinical Research Ed.)|January 11, 2013
Androgen deprivation treatment in prostate cancerBenjamin C Thomas, David E Neal
Current Cancer Drug Targets|August 20, 2010
RAS pathways in prostate cancer - mediators of hormone resistance?Hayley C Whitaker, David E Neal
Nature Clinical Practice. Urology|January 29, 2009
Treatment for PSA screen-detected prostate cancer: what are the options?R Tim D Oliver, David E Neal
Nature Clinical Practice. Urology|February 14, 2006
Fournier's gangreneTevita 'Aho, Alessandra Canal, David E Neal
Molecular & Cellular Oncology|June 18, 2016
Kinase joins the chaperone club: Androgen-regulated kinome reveals choline kinase alpha as a potential drug target in prostate cancerMohammad Asim, Charlie E Massie, David E Neal
Pageof 31

Showing results (1-10 of 302) with videos related to

Sort By:
Pageof 31
The Lancet. Oncology|July 6, 2010
PSA testing for prostate cancer improves survival--but can we do better?David E Neal
Nature Clinical Practice. Urology|February 14, 2006
Molecular medicine and its impact on practiceDavid E Neal
The Journal of Urology|August 19, 2008
Can we accurately identify men with low risk prostate cancer?David E Neal
BJU International|April 5, 2013
Targeting the pro-survival side-effects of androgen-deprivation therapy in prostate cancerVincent Zecchini, David E Neal
The Practitioner|December 3, 2003
Key questions in benign prostatic hyperplasiaDavid E Neal, Paul Hegarty
BMJ (Clinical Research Ed.)|January 11, 2013
Androgen deprivation treatment in prostate cancerBenjamin C Thomas, David E Neal
Current Cancer Drug Targets|August 20, 2010
RAS pathways in prostate cancer - mediators of hormone resistance?Hayley C Whitaker, David E Neal
Nature Clinical Practice. Urology|January 29, 2009
Treatment for PSA screen-detected prostate cancer: what are the options?R Tim D Oliver, David E Neal
Nature Clinical Practice. Urology|February 14, 2006
Fournier's gangreneTevita 'Aho, Alessandra Canal, David E Neal
Molecular & Cellular Oncology|June 18, 2016
Kinase joins the chaperone club: Androgen-regulated kinome reveals choline kinase alpha as a potential drug target in prostate cancerMohammad Asim, Charlie E Massie, David E Neal
Pageof 31